These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17397121)

  • 21. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
    Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
    J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.
    Mahaney PE; Gavrin LK; Trybulski EJ; Stack GP; Vu TA; Cohn ST; Ye F; Belardi JK; Santilli AA; Sabatucci JP; Leiter J; Johnston GH; Bray JA; Burroughs KD; Cosmi SA; Leventhal L; Koury EJ; Zhang Y; Mugford CA; Ho DM; Rosenzweig-Lipson SJ; Platt B; Smith VA; Deecher DC
    J Med Chem; 2008 Jul; 51(13):4038-49. PubMed ID: 18557608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
    Schilling S; Zeitschel U; Hoffmann T; Heiser U; Francke M; Kehlen A; Holzer M; Hutter-Paier B; Prokesch M; Windisch M; Jagla W; Schlenzig D; Lindner C; Rudolph T; Reuter G; Cynis H; Montag D; Demuth HU; Rossner S
    Nat Med; 2008 Oct; 14(10):1106-11. PubMed ID: 18836460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of Alzheimer's disease amyloid plaque load in transgenic mice by D3, A D-enantiomeric peptide identified by mirror image phage display.
    van Groen T; Wiesehan K; Funke SA; Kadish I; Nagel-Steger L; Willbold D
    ChemMedChem; 2008 Dec; 3(12):1848-52. PubMed ID: 19016284
    [No Abstract]   [Full Text] [Related]  

  • 25. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors.
    Fisher A
    Neurodegener Dis; 2008; 5(3-4):237-40. PubMed ID: 18322400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." The blood-brain barrier: a physical and conceptual challenge.
    Hachinski V; Lee TY
    Alzheimers Dement; 2009 Sep; 5(5):435-6. PubMed ID: 19751924
    [No Abstract]   [Full Text] [Related]  

  • 27. Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease?
    Klausner AP; Sharma S; Fletcher S; Neff P; Yang SK; Son H; Tuttle JB; Steers WD
    J Urol; 2008 Mar; 179(3):1173-7. PubMed ID: 18206173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.
    Adlard PA; Cherny RA; Finkelstein DI; Gautier E; Robb E; Cortes M; Volitakis I; Liu X; Smith JP; Perez K; Laughton K; Li QX; Charman SA; Nicolazzo JA; Wilkins S; Deleva K; Lynch T; Kok G; Ritchie CW; Tanzi RE; Cappai R; Masters CL; Barnham KJ; Bush AI
    Neuron; 2008 Jul; 59(1):43-55. PubMed ID: 18614028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies.
    Frydman-Marom A; Rechter M; Shefler I; Bram Y; Shalev DE; Gazit E
    Angew Chem Int Ed Engl; 2009; 48(11):1981-6. PubMed ID: 19035593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Don't underestimate the value of transgenic animal models of Alzheimer disease].
    Nilsson LN; Lannfelt L; Basun H; Nordberg A; Winblad B
    Lakartidningen; 2007 Mar 7-13; 104(10):798-9; discussion 799-800. PubMed ID: 17432800
    [No Abstract]   [Full Text] [Related]  

  • 31. Targeting the insulin-regulated aminopeptidase/AT4 receptor for cognitive disorders.
    Hallberg M
    Drug News Perspect; 2009 Apr; 22(3):133-9. PubMed ID: 19440555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease.
    He J; Luo H; Yan B; Yu Y; Wang H; Wei Z; Zhang Y; Xu H; Tempier A; Li X; Li XM
    Neurobiol Aging; 2009 Aug; 30(8):1205-16. PubMed ID: 18079026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models.
    van Groen T; Kadish I; Wiesehan K; Funke SA; Willbold D
    ChemMedChem; 2009 Feb; 4(2):276-82. PubMed ID: 19072935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lesions and genes: on the edge of improved isomorphic models for Alzheimer's disease?
    Gonzalez de Aguilar JL; Loeffler JP; Boutillier AL
    Neurodegener Dis; 2008; 5(5):318-20. PubMed ID: 18520166
    [No Abstract]   [Full Text] [Related]  

  • 35. Anatomical and functional phenotyping of mice models of Alzheimer's disease by MR microscopy.
    Benveniste H; Ma Y; Dhawan J; Gifford A; Smith SD; Feinstein I; Du C; Grant SC; Hof PR
    Ann N Y Acad Sci; 2007 Feb; 1097():12-29. PubMed ID: 17413006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neural network dysfunction in Alzheimer's disease: a drug development perspective.
    Small DH
    Drug News Perspect; 2007 Nov; 20(9):557-63. PubMed ID: 18176660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Alzheimer's disease: therapeutic perspectives].
    Dubois B; De Souza L; Allali G; Kalafat M; Sarazin M
    Bull Acad Natl Med; 2008 Feb; 192(2):333-42; discussion 343-4. PubMed ID: 18819687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
    Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
    Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Animal models of Alzheimer's disease and frontotemporal dementia.
    Götz J; Ittner LM
    Nat Rev Neurosci; 2008 Jul; 9(7):532-44. PubMed ID: 18568014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.